Extensive research on human microbiomes has largely focused on the human gut and the contribution of microbiome dysbiosis (loss of key taxa, diversity, and metabolic capacity) in the onset of diseases. Other studies have focused on additional compartments in the human body, such as the biliary system. These compartments also have an autochthonous microbiome that undergoes changes depending on the conditions of the host and vice versa. However, comprehensive studies characterizing the human bile microbiome and its relationship to liver diseases are still scarce.

Therefore, we focused on the relationship between the bile microbiome and primary sclerosing cholangitis (PSC), a difficult-to-treat liver disease and, as such, an indication for liver transplantation. PSC is characterized by progressive fibrosis and inflammation of the bile ducts with ulcerative lesions of the bile duct epithelia.\(^1\) Although PSC is frequently associated with bacterial infections, it can also lead to bile duct cancer and liver cirrhosis.\(^1\) To date, the pathogenesis of PSC remains unknown, and its diagnosis is challenging. Recent studies have pointed to the bile microbiome as a key player in the pathophysiology of PSC.\(^2\) Until the recent advances in microbiome research, healthy human bile had been considered sterile.\(^3\) However, microbiome studies have not only revealed the presence of a bile microbiome but also an alteration within the microbiome in patients with PSC compared with healthy individuals.\(^4,5\) Unlike the physical composition of bile, its microbial composition remains largely unknown. Bile is a biological fluid, mainly constituted of bile acids, cholesterol, phospholipids, and proteins. It is synthesized in the liver and stored in the gallbladder. Several bile-related diseases modify the functionality of bile, of which the most frequent is the generation of gallstones resulting in cholestasis. Another bile-related disease is bile duct inflammation, or cholangitis.

In previous studies, we examined different compartments of the human body that were considered to be sterile (portal, hepatic, and peripheral veins and the right atrium), as well as fluid samples of ascites patients and blood samples from patients with chronic liver disease (CLD). We found bacterial DNA and differences in the composition of the bacterial community in all compartments investigated.\(^4,5\)

Here, we aimed to characterize the biliary microbiome of PSC patients compared with control individuals and to patients with other biliary diseases, such as cholangitis and cholestasis in a cross-sectional pilot study.

**Patients and Methods**

In this study, we characterized the bile microbiome of PSC patients \(n = 5\), cholestasis patients \(n = 6\), and
Bile Microbiome Compared With Other Human Compartments

The analysis of the sequencing data showed that the composition of the human bacterial bile microbiome differs strongly from the composition of the bacterial microbiome from other human samples like blood, ascites, or stool (Fig. 1A-D). Furthermore, the quantity and profile of bacterial DNA in the bile samples differed from those found in the negative control patients (Supporting Fig. 1), clearly demonstrating that the bacteria detected in bile fluid are not a contamination deriving from the negative control patients. Detailed microbiome analysis revealed that the bile microbiome consists of bacteria belonging to 8 different phyla, namely, Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, Gemmatimonadetes, Proteobacteria, Saccharibacteria, and Tenericutes. However, only 5 phyla account for almost the entire bile microbiome. These are Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and Proteobacteria (Fig. 1E). Proteobacteria and in particular Gammaproteobacteria were the most abundant class of bacteria followed by the phylum of Firmicutes and, in particular, bacteria belonging to the class of Bacilli.

Bile Microbiome in PSC Patients

In our first analysis, we compared the bile microbiome of PSC patients (n = 4) with the bacterial microbiome of the control group (n = 3). The analysis revealed that the microbiome composition differed between PSC patients and that of the control group, similar to the results published by Liwinski et al. Although the abundance of Actinobacteria, Bacteroidetes, Firmicutes, and Fusobacteria was lower in PSC patients, the abundance of Proteobacteria was greater compared with patients from the control group (Fig. 1E). Core microbiome analysis revealed that both groups harbored a diverse core microbiome, with *Streptococcus* as the predominant genus in the core microbiome of the control group and that of PSC patients (Fig. 1F,G).

Interestingly, on the bacterial species level, patients with PSC showed a lower abundance of several bacterial species, and their core microbiome consisted of fewer bacterial species than the core
microbiome of the control group (shown in Fig. 1G), reinforcing the concept of biliary dysbiosis of the bile fluid being pathophysiologically relevant for the formation of PSC. Pairwise analysis between PSC patients and the control group using Linear discriminant analysis effect size (LEfSe) revealed differences in the bacterial microbiome composition at the bacterial family level. Bacteria belonging to the family of Pasteurellaceae and Pseudomonadaceae were more abundant in the bile microbiome of PSC patients, whereas, bacteria belonging to the families of Prevotellaceae and Bifidobacteriaceae were more...
Abundant in the control group, indicating dysbiosis of the bile microbiome in PSC patients (Fig. 2E). Alpha diversity analysis showed that PSC patients had a significantly lower alpha diversity (at the phylum level) than the control group ($P < 0.05$) (data not shown).
Bile Microbiome in Cholestasis and Cholangitis

In a second analysis, we investigated the microbiome composition of cholestasis (n = 6) and cholangitis (n = 5) patients and compared it with the microbiome composition found in PSC patients and the control group. Microbiome analysis on the phylum level revealed that the bacterial bile microbiome composition differed between these patient groups (Fig. 2A-D).

BILE MICROBIOME IN CHOLESTASIS

Comparisons of the microbiome from patients with cholestasis with the microbiome of the control group revealed that bacteria belonging to the families of Corynebacteriaceae and Ruminococcaceae were more abundant in samples from the control group. Additionally, bacteria belonging to the families of Oxalobacteraceae and Burkholderiaceae were more abundant in the control group (Fig. 2E). Comparison of cholestasis patients with PSC patients revealed that bacteria belonging to the families of Comamonadaceae and Burkholderiaceae were more abundant in PSC patients. Comparison at the phylum level revealed that the proportion of bacteria belonging to the phylum Proteobacteria was lower, whereas the proportion of Actinobacteria and Firmicutes was higher (Fig. 2C). Interestingly, cholestasis patients had the highest alpha diversity.

BILE MICROBIOME IN CHOLANGITIS

Analysis on the phylum level showed that in cholangitis patients, the proportion of Bacteroidetes was decreased, while the proportion of Proteobacteria was higher than in the control group (Fig. 2D). Bacteria belonging to the families of Microbacteriaceae, Veillonellaceae, and Burkholderiaceae were more abundant in the control group patients than in patients with cholangitis (Fig. 2E). The comparison of the bile microbiome of cholangitis patients with that of cholestasis patients revealed bacteria belonging to the family of Burkholderiaceae to be more abundant in cholangitis patients. Comparisons of cholestasis patients with cholangitis patients showed that bacteria belonging to the families of Staphylococcaceae and Microbacteriaceae were more abundant in cholestasis patients (Fig. 2E).

Analysis on OTU numbers revealed significant differences in OTU richness between the 4 patient groups (P < 0.05). These results indicate that the bacterial diversity of the bile microbiome depends on the biliary pathology. Additionally, there was no major difference or variance within the 5 cholangitis patients and in the other patient groups, indicating that the microbiome composition within the groups was reliable.

This study has several limitations. Because of the small sample size of the data set, we cannot account for antibiotics or Proton-pump inhibitor use. However, statistical analysis between the study patients revealed that this had no significant effect on their microbiome composition at the phylum level (P > 0.05).

In summary, our results confirm recently published data on the bile microbiome composition in PSC patients, emphasizing the reproducibility of bile microbiome assessment. Moreover, we show that the composition of the bile microbiome differed between patients exhibiting different biliary pathologies. However, additional work is needed to address any causality of the microbiome composition and its pathogenesis in biliary diseases.

Acknowledgments: This study was funded by the MICROB-PREDICT project, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant 825694. The authors would like to thank Sabine Dentler for English proofreading.
Florence Servant, M.Sc., Dr. med. 6
Manimozhiyan Arumugam, Dr. med. 3,7
Aleksander Krag, Ph.D. 3,4
Benjamin Leouvier, Ph.D., Dr. med. 6
Tobias J. Weismüller, Dr. med. 2**, Jonel Trebicka, Ph.D. 1,8**

1 Translational Hepatology
Department of Internal Medicine I
University Hospital Frankfurt
Goethe University
Frankfurt, Germany
2 Department of Internal Medicine I
University Hospital Bonn
University of Bonn
Bonn, Germany
3 Department of Gastroenterology and Hepatology
Odense University Hospital
Odense, Denmark
4 Department of Clinical Research
University of Southern Denmark
Odense, Denmark
5 Chirurgische Klinik
Universitätsklinikum Erlangen
Erlangen, Germany
6 Vaiomer SAS
7 Novo Nordisk Foundation Center for Basic Metabolic Research
Faculty of Health and Medical Sciences
University of Copenhagen
Copenhagen, Denmark
8 European Foundation for the Study of Chronic Liver Failure
Barcelona, Spain

REFERENCES

1) Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis—a comprehensive review. J Hepatol 2017; 67:1298-1323.
2) Liwinski T, Zenouzi R, John C, Ehlken H, Rühlemann MC, Bang C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut 2020;69:665-672.
3) Warburton RC, Gelson W, Harper S, Rushbrook S, Narbad A. Human bile retrieved from the normal biliary system is not sterile. J Hepatol 2017;66:S65.
4) Alvarez-Silva C, Schierwagen R, Pohlmann A, Magdaleno F, Uschner FE, Ryan P, et al. Compartmentalization of immune response and microbial translocation in decompensated cirrhosis. Front Immunol 2019;10:69.
5) Schierwagen R, Alvarez-Silva C, Madsen MSA, Kolbe CC, Meyer C, Thomas D, et al. Circulating microbiome in blood of different circulatory compartments. Gut 2019;68:578-580.